Fundamental Analysis of Q32 BIO INC(NASDAQ:QTTB) stock

Fundamental Rating

Overall QTTB gets a fundamental rating of 2 out of 10. We evaluated QTTB against 568 industry peers in the Biotechnology industry. QTTB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. QTTB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year QTTB has reported negative net income.

In the past year QTTB has reported a negative cash flow from operations.

QTTB had negative earnings in each of the past 5 years.

QTTB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

QTTB has a Return On Assets (-47.51%) which is comparable to the rest of the industry.

Looking at the Return On Equity, with a value of -271.46%, QTTB is doing worse than 72.57% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-47.51%
ROE	-271.46%
ROIC	N/A

ROA(3y)-60.34%

ROA(5y)-52.65%

ROE(3y)-71.33%

ROE(5y)-63.97%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QTTB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.

QTTB has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, QTTB has less shares outstanding

QTTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

QTTB has an Altman-Z score of -3.68. This is a bad value and indicates that QTTB is not financially healthy and even has some risk of bankruptcy.

QTTB has a Altman-Z score (-3.68) which is comparable to the rest of the industry.

QTTB has a Debt/Equity ratio of 0.61. This is a neutral value indicating QTTB is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.61, QTTB is not doing good in the industry: 75.40% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Altman-Z	-3.68

ROIC/WACCN/A

WACC11.78%

2.3 Liquidity

A Current Ratio of 6.53 indicates that QTTB has no problem at all paying its short term obligations.

The Current ratio of QTTB (6.53) is better than 65.49% of its industry peers.

A Quick Ratio of 6.53 indicates that QTTB has no problem at all paying its short term obligations.

With a decent Quick ratio value of 6.53, QTTB is doing good in the industry, outperforming 65.66% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.53
Quick Ratio	6.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

QTTB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.37%.

The Revenue for QTTB has decreased by -100.00% in the past year. This is quite bad

Measured over the past years, QTTB shows a very negative growth in Revenue. The Revenue has been decreasing by -26.31% on average per year.

EPS 1Y (TTM)-2.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%85.77%

Revenue 1Y (TTM)-100%

Revenue growth 3Y-24.63%

Revenue growth 5Y-26.31%

Sales Q2Q%N/A

3.2 Future

QTTB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.93% yearly.

Based on estimates for the next years, QTTB will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.

EPS Next Y79.86%

EPS Next 2Y33.62%

EPS Next 3Y20.93%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

QTTB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year QTTB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

QTTB's earnings are expected to grow with 20.93% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.62%

EPS Next 3Y20.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

QTTB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Q32 BIO INC

NASDAQ:QTTB (12/18/2024, 3:39:09 PM)

3.0489

-0.38 (-11.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap37.14M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-47.51%
ROE	-271.46%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.53
Quick Ratio	6.53
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-2.37%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y79.86%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3Y-24.63%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

Q32 BIO INC (QTTB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens